Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060087 | 0.92 | ESR1 (0.49) | ESR1TTRDPP4APPKMT2A | |
| SCHEMBL4060081 | 0.92 | ESR1 (0.49) | ESR1TTRDPP4APPKMT2A | |
| SCHEMBL5396213 | 0.87 | PPARA (0.51) | CNR2APPKMT2AMEN1MAPT | |
| SCHEMBL5396218 | 0.87 | PPARA (0.51) | CNR2APPKMT2AMEN1MAPT | |
| SCHEMBL4548370 | 0.85 | ESR1 (0.59) | ESR1KMT2AMEN1MAPTMAOB | |
| SCHEMBL1399888 | 0.85 | ESR1 (0.59) | ESR1KMT2AMEN1MAPTMAOB | |
| SCHEMBL7693884 | 0.84 | MAPT (0.53) | ESR1KMT2AMAPTALDH1A1MAOB | |
| SCHEMBL799522 | 0.84 | MAPT (0.53) | ESR1KMT2AMAPTALDH1A1MAOB | |
| SCHEMBL30628952 | 0.84 | PTPN1 (0.48) | ESR1TTRAPPKMT2AMEN1 | |
| SCHEMBL26750709 | 0.84 | PTPN1 (0.48) | ESR1TTRAPPKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | BTD, HLCS, TYR | ESR1 262/4885CNR2 3196/4885TTR 968/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | ESR1 1001/4885CNR2 52/4885TTR 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.